NCT06592638View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

Trial Locations (6)

33322

RECRUITING

Zelgen Site 102, Plantation

40536

RECRUITING

Zelgen Site 103, Lexington

44106

NOT_YET_RECRUITING

Zelgen Site 104, Cleveland

44718

RECRUITING

Zelgen Site 101, Canton

77030

NOT_YET_RECRUITING

Zelgen Site 106, Houston

92868

NOT_YET_RECRUITING

Zelgen Site 105, Orange

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY